奥希替尼治疗中一过性无症状肺部阴影及其临床意义
该回顾性研究分析了74例接受奥希替尼治疗的EGFR T790M突变NSCLC患者,发现20.3%出现一过性无症状肺部阴影(TAPO),中位出现时间24.0周,中位持续时间6.0周,继续奥希替尼治疗下TAPO阳性组暴露时间显著更长(25.0个月 vs 13.0个月,p=0.009),生存数值上更长但未达统计学显著。
要点
- 奥希替尼治疗中TAPO发生率20.3%,中位出现时间24.0周,持续时间6.0周。
- TAPO最常见影像模式为隐源性机化性肺炎和/或单纯性嗜酸性肺炎。
- TAPO阳性组奥希替尼暴露时间显著更长(25.0个月 vs 13.0个月,p=0.009)。
核心结论
- TAPO在奥希替尼治疗中常见,可能被误认为孤立性肺进展或药物性ILD,但缺乏严重临床恶化时继续奥希替尼并定期CT随访是合理的。
研究设计与样本
- 回顾性分析74例EGFR T790M突变NSCLC患者,由胸部放射科医生独立审查系列CT,按影像模式分类TAPO并分析其与临床结局的相关性。
主要发现
- 74例中15例(20.3%)发现TAPO,中位出现时间24.0周(范围1-72周),中位持续时间6.0周(范围5-24周),期间继续奥希替尼治疗。
- TAPO最常见影像模式包括隐源性机化性肺炎和/或单纯性嗜酸性肺炎。
- TAPO阳性与阴性组患者特征无显著差异。
- TAPO阳性组奥希替尼暴露时间显著长于阴性组(25.0个月 vs 13.0个月,p=0.009)。
- TAPO阳性组中位PFS和OS数值上更长(PFS 22个月 vs 15个月,p=0.293;OS 37个月 vs 24个月,p=0.059)。
临床怎么用
- 奥希替尼治疗中出现TAPO且无严重临床恶化时,可继续奥希替尼并定期CT随访,避免误判为疾病进展或ILD。
局限性
- 回顾性研究,样本量74例,需长期随访和大规模研究进一步临床验证TAPO。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Osimertinib is an oral, potent, irreversible third-generation EGFR tyrosine kinase inhibitor approved for the treatment of T790M-positive NSCLC patients who failed first- or second-generation EGFR tyrosine kinase inhibitors. Interstitial lung disease (ILD) is a rare complication with osimertinib, occurring in 1% to 3% of patients. Recently, a relatively high incidence of transient asymptomatic pulmonary opacities (TAPOs), which are different from ILD, has been described. However, its clinical implication has not been fully determined yet. METHODS: We retrospectively analyzed 74 EGFR T790M mutant NSCLC patients treated with osimertinib. Serial computed tomographic findings were reviewed by a thoracic radiologist independently, and TAPO was classified according to its radiologic pattern. We also analyzed the correlation of TAPO with clinical outcomes. RESULTS: Among 74 patients, TAPOs were found in 15 (20.3%). The median time to TAPO development was 24.0 weeks (range, 1 to 72 weeks) and the median duration of TAPO was 6.0 weeks (range, 5 to 24 weeks) during continued osimertinib treatment. The most common radiological patterns of TAPO include cryptogenic organizing pneumonia and/or simple eosinophilic pneumonia. There was no significant difference in patient characteristics between TAPO-positive and -negative groups. The duration of exposure to osimertinib was significantly longer in TAPO-positive than -negative groups (25.0 months versus 13.0 months, p = 0.009). The median progression-free survival and the median overall survival was numerically longer in TAPO-positive than -negative groups (22 months versus 15 months for progression-free survival, p = 0.293; 37 months versus 24 months for overall survival, p = 0.059), respectively. CONCLUSIONS: TAPOs are frequently observed with osimertinib treatment and may be mistaken for isolated pulmonary progression or drug-induced ILD. Given the lack of serious clinical deterioration, it is reasonable to continue osimertinib with regular computed tomographic-scan follow-up. For further clinical validation of TAPOs, long-term follow-up and large studies are warranted.
引用
- Lee H, Lee HY, Sun JM, et al. Transient Asymptomatic Pulmonary Opacities During Osimertinib Treatment and its Clinical Implication. J Thorac Oncol. 2018. PMID: 29775809. doi:10.1016/j.jtho.2018.04.038
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。